



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 29 Oct 2018 (#33)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important Notices

- The [International Summit in Human Genetics and Genomics](#), sponsored by the National Human Genome Research Institute (NHGRI), other Institutes and Centers at NIH, and the Foundation for the NIH, will train early-mid career stage health care professionals and trainees from developing nations. Research scientists, physicians, dentists, dentist-scientists, nurses, counselors and medical, dental and graduate school trainees can apply. Selected candidates will be fully sponsored (travel, local transportation, lodging, per diem) for the duration of the Summit, August 28 - September 28, 2019. Selections are on a rolling basis and seats are limited so please apply early. Application deadline: December 10, 2018
- Publication of the Revised NIH Grants Policy Statement (Rev. October 2018) for FY 2019 ([NOT-OD-19-021](#))
- *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Policy on Monitoring and Oversight of Clinical Trials ([NOT-HD-18-020](#))
- Notice Inviting the Community to Contribute to the Generation of National Human Genome Research Institute (NHGRI's) '2020 Vision for Genomics' ([NOT-HG-19-005](#))
- Notice of Information: National Institute of Mental Health (NIMHs) Interest in Areas of Stress Biology Research ([NOT-MH-18-058](#))
- **Upcoming Deadlines**
  - [Emerging Global Leader Award](#) November 28, 2018
  - [Global Brain and Nervous System Disorders Research Across the Lifespan](#) November 7, 2018
  - [Chronic, Noncommunicable Diseases and Disorders Research Training](#) November 13, 2018
  - [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) a joint National Institutes of Health (NIH) - National Science Foundation (NSF) initiative. November 21, 2018. **Apply through NSF program solicitation.** Estimated Number of Awards: 8 and Anticipated Funding Amount: \$20,000,000. Full Proposal Deadline(s) (due by 5 p.m. submitter's local time): November 21, 2018, Third Wednesday in November, Annually Thereafter
  - [Health-Professional Education Partnership Initiative \(HEPI\)](#) in Malawi and Zambia December 13, 2018
  - [Planning for Noncommunicable Diseases and Disorders Research Training](#) March 14, 2019

### 1. A Census of Cells and Circuits in the Aging Brain (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AG-19-027\)](#)

**Type:** R01

**Application Due Date:** March 8, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) intends to support pilot studies aimed to establish molecular, anatomical, and functional cell and circuit census data from selected brain regions of young and old C57 BL/6J mice. This will complement and build on current BRAIN Initiative efforts while informing a design for a comprehensive characterization of cells and circuits in the brain across the lifespan, including the generation of a comprehensive 3D brain cell reference atlas of the aging mouse brain.

**Budget:** NIA intends to commit \$2.5 million in FY 2019 to fund 2-3 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-FD-20-001\)](#)

**Type:** R01

**Application Due Date:** June 25, 2019, by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to support clinical studies of products that address unmet needs in rare diseases or conditions or provide highly significant improvements in treatment or diagnosis. Through the support of efficient and innovative clinical studies evaluating safety and/or effectiveness, FDA expects to increase the number of treatments for rare diseases with an unmet medical need and support studies that will either result in market approval of these products or substantially contribute to the essential data needed for medical product development that will ultimately meet the needs of rare disease patients.

**Budget:** Application budgets need to reflect the actual needs of the proposed project including both direct and indirect costs). Applicants requesting \$500,000 or more in direct costs in any year must contact the Scientific/ Research Contact at least 4 weeks prior to the application deadline. Approval for requests over \$500,000 must be included as an attachment in the final submission. Applications submitted without this approval will not be reviewed. The scope of the proposed project should determine the project period. The maximum project period is four (4) years, however, the length of support will depend on the nature of the study. For those studies with an expected duration of more than 1 year, a second, third, or fourth year of noncompetitive continuation of support will depend on the following factors: (1) Performance during the preceding year; (2) compliance with regulatory requirements of IND/investigational device exemption (IDE), if applicable; and (3) availability of Federal funds.

### 3. Early Screening for Autism Spectrum Disorder (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-MH-19-120\)](#)  
[\(RFA-MH-19-121\)](#)

**Type:** R01  
R21

**Application Due Date:** February 4, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R01 grant mechanism, while RFA-MH-19-121 uses the R21 grant mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for the R21 mechanism. Applications with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may be more appropriate for this FOA (R01 mechanism).

**Budget:** The following NIH components intend to commit the following amounts in FY 2019: NIMH, \$4 Million, 8-10 awards to this FOA and its companion NIDCD, \$500K in direct costs to this FOA and its companion NINDS, \$500K in direct costs to this FOA and its companion. R01 - Direct costs are limited to \$500,000 in any one year. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)